Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation-Reference-Cited by-同舟云学术

Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation

Published:2024-03 Issue: Volume:199 Page:113537
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Cohen Romain,Raeisi Morteza,Chibaudel Benoist,Yoshino Takayuki,Shi Qian,Zalcberg John R.,Adams Richard,Cremolini Chiara,Grothey Axel,Mayer Robert J.,Van Cutsem Eric,Tabernero Josep,Bando Hideaki,Misumi Toshihiro,Overman Michael J.,André Thierry,de Gramont Aimery

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Center for Drug Evaluation and Research. Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry. US Food and Drug Administration 2019. 〈https://www.fda.gov/regulatory-information/search-fda-guidance-documents/placebos-and-blinding-randomized-controlled-cancer-clinical-trials-drug-and-biological-products〉 (accessed December 26, 2023).

2. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer;André;N Engl J Med,2020

3. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study;Cohen;J Immunother Cancer,2020

4. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer;Overman;JCO,2018

5. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142;André;Ann Oncol,2022